ADBE vs PFE: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
Adobe Inc. · Technology
$238.25
+13.5% upside to fair value
Med Conviction
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
ADBE has more upside to fair value
(+13.5%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
PFE |
| Current Price |
$238.25 |
$27.64 |
| Fair Value Estimate |
$270.38 |
$30.94 |
| Upside to Fair Value |
+13.5%
|
+12.0%
|
| Market Cap |
$94.7B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
9.5x
|
17.4x
|
| Price / Sales |
3.6x
|
2.5x
|
| Price / FCF |
8.6x
|
14.3x
|
| Revenue Growth YoY |
+12.9%
|
+2.6%
|
| Gross Margin |
89.1%
|
71.3%
|
| Operating Margin |
35.7%
|
25.1%
|
| Return on Equity |
62.9%
|
4.9%
|
| Dividend Yield |
0% |
6.22% |
| FCF Yield |
11.63%
|
6.97%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Adobe is a global software provider organized into Digital Media, Digital Experience, and Publishing and Advertising, with Creative Cloud as its subscription flagship and Document Cloud as its cloud-native document platform. The business quality is high on fundamentals: TTM gross margin of 89.1%, TTM operating margin of 35.7%, TTM net margin of 28.0%, ROE of 62.9%, and free cash flow of $27.69 pe…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
ADBE |
PFE |
| Zone Low |
$202.78 |
$23.21 |
| Zone High |
$229.82 |
$26.30 |
| In Buy Zone? |
No
|
No
|